<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Meneghini, Luigi F.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">New Basal Insulins: The Longer the Better?</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">37-37</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses evidence supporting the efforts to develop longer-acting insulin therapy. The importance of insulin therapy and associated glycemic control is incontestable. Prior to the discovery of insulin in the early 1920s, the life expectancy of a 10-year-old diagnosed with type 1 diabetes was only 2.6 years. In the early years following the introduction of insulin, the life expectancy of a 10-year-old patient with diabetes had increased to 24.3 years and had leapt to 55 years 2 decades later [Joslin EP. Diabetic Manual for the Doctor and Patient, 9th Ed. 1957].</style></abstract><number><style face="normal" font="default" size="100%">17</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>